U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07598370) titled 'A Study of LY3439539 in Participants With Alzheimer's Disease' on May 14.
Brief Summary: The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.
Participation in the study will last approximately 9 months with visits about once a month.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Intervention:
DRUG: LY3439539
Administered IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by HT Syndication....